Does the media refer more to REGN or ALNY?

In the previous week, Regeneron Pharmaceuticals had 34 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 42 mentions for Regeneron Pharmaceuticals and 8 mentions for Alnylam Pharmaceuticals. Regeneron Pharmaceuticals' average media sentiment score of 0.51 beat Alnylam Pharmaceuticals' score of 0.19 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regeneron Pharmaceuticals 13 Very Positive mention(s) 7 Positive mention(s) 13 Neutral mention(s) 3 Negative mention(s) 2 Very Negative mention(s) Positive Alnylam Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ALNY or MRNA?

In the previous week, Moderna had 32 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 40 mentions for Moderna and 8 mentions for Alnylam Pharmaceuticals. Moderna's average media sentiment score of 0.27 beat Alnylam Pharmaceuticals' score of 0.19 indicating that Moderna is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Moderna 7 Very Positive mention(s) 15 Positive mention(s) 8 Neutral mention(s) 9 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer NTRA or ALNY?

In the previous week, Alnylam Pharmaceuticals had 2 more articles in the media than Natera. MarketBeat recorded 8 mentions for Alnylam Pharmaceuticals and 6 mentions for Natera. Natera's average media sentiment score of 0.50 beat Alnylam Pharmaceuticals' score of 0.19 indicating that Natera is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Natera 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alnylam Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ALNY or ARGX?

In the previous week, Alnylam Pharmaceuticals had 5 more articles in the media than argenex. MarketBeat recorded 8 mentions for Alnylam Pharmaceuticals and 3 mentions for argenex. Alnylam Pharmaceuticals' average media sentiment score of 0.19 beat argenex's score of 0.05 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral argenex 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer RVMD or ALNY?

In the previous week, Revolution Medicines had 6 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 14 mentions for Revolution Medicines and 8 mentions for Alnylam Pharmaceuticals. Revolution Medicines' average media sentiment score of 0.57 beat Alnylam Pharmaceuticals' score of 0.19 indicating that Revolution Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alnylam Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Alnylam Pharmaceuticals (ALNY) Competitors

$219.72 -11.46 (-4.96%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$220.10 +0.38 (+0.17%)

As of 10/2/2026 07:49 PM Eastern

Compare

ALNY vs. REGN, MRNA, NTRA, ARGX, and RVMD

Should you buy Alnylam Pharmaceuticals stock or one of its competitors? Alnylam Pharmaceuticals's main competitors and comparable companies include Regeneron Pharmaceuticals (REGN), Moderna (MRNA), Natera (NTRA), argenex (ARGX), and Revolution Medicines (RVMD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Alnylam Pharmaceuticals compare to Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals (NASDAQ:REGN) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, media sentiment, profitability, dividends, analyst recommendations, risk, valuation and institutional ownership.

Regeneron Pharmaceuticals has higher revenue and earnings than Alnylam Pharmaceuticals. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regeneron Pharmaceuticals	$14.34B	5.28	$4.50B	$40.46	18.17
Alnylam Pharmaceuticals	$3.71B	7.92	$313.75M	$5.38	40.84

Regeneron Pharmaceuticals has a net margin of 27.86% compared to Alnylam Pharmaceuticals' net margin of 15.26%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Regeneron Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regeneron Pharmaceuticals	27.86%	13.47%	10.34%
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%

Regeneron Pharmaceuticals has a beta of 0.16, indicating that its stock price is 84% less volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.28, indicating that its stock price is 72% less volatile than the broader market.

Regeneron Pharmaceuticals presently has a consensus price target of $809.50, indicating a potential upside of 10.11%. Alnylam Pharmaceuticals has a consensus price target of $366.90, indicating a potential upside of 66.99%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Alnylam Pharmaceuticals is more favorable than Regeneron Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regeneron Pharmaceuticals	0 Sell rating(s)	9 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	2.69
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.83

83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are held by insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Regeneron Pharmaceuticals had 34 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 42 mentions for Regeneron Pharmaceuticals and 8 mentions for Alnylam Pharmaceuticals. Regeneron Pharmaceuticals' average media sentiment score of 0.51 beat Alnylam Pharmaceuticals' score of 0.19 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regeneron Pharmaceuticals	13 Very Positive mention(s)	7 Positive mention(s)	13 Neutral mention(s)	3 Negative mention(s)	2 Very Negative mention(s)	Positive
Alnylam Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Alnylam Pharmaceuticals beats Regeneron Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Alnylam Pharmaceuticals compare to Moderna?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Moderna (NASDAQ:MRNA) are both large-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

Alnylam Pharmaceuticals has a beta of 0.28, indicating that its share price is 72% less volatile than the broader market. Comparatively, Moderna has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market.

In the previous week, Moderna had 32 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 40 mentions for Moderna and 8 mentions for Alnylam Pharmaceuticals. Moderna's average media sentiment score of 0.27 beat Alnylam Pharmaceuticals' score of 0.19 indicating that Moderna is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Moderna	7 Very Positive mention(s)	15 Positive mention(s)	8 Neutral mention(s)	9 Negative mention(s)	1 Very Negative mention(s)	Neutral

Alnylam Pharmaceuticals presently has a consensus target price of $366.90, suggesting a potential upside of 66.99%. Moderna has a consensus target price of $77.83, suggesting a potential downside of 59.04%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Alnylam Pharmaceuticals is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.83
Moderna	5 Sell rating(s)	13 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.08

93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are held by company insiders. Comparatively, 10.8% of Moderna shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Alnylam Pharmaceuticals has a net margin of 15.26% compared to Moderna's net margin of -141.43%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%
Moderna	-141.43%	-28.30%	-19.39%

Alnylam Pharmaceuticals has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$3.71B	7.92	$313.75M	$5.38	40.84
Moderna	$1.94B	39.02	-$2.82B	-$7.99	N/A

Summary

Alnylam Pharmaceuticals beats Moderna on 12 of the 17 factors compared between the two stocks.

How does Alnylam Pharmaceuticals compare to Natera?

Natera (NASDAQ:NTRA) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Natera presently has a consensus price target of $341.55, indicating a potential downside of 16.77%. Alnylam Pharmaceuticals has a consensus price target of $366.90, indicating a potential upside of 66.99%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Alnylam Pharmaceuticals is more favorable than Natera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Natera	1 Sell rating(s)	4 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.83
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.83

Alnylam Pharmaceuticals has a net margin of 15.26% compared to Natera's net margin of -7.11%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Natera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Natera	-7.11%	-11.38%	-7.87%
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%

In the previous week, Alnylam Pharmaceuticals had 2 more articles in the media than Natera. MarketBeat recorded 8 mentions for Alnylam Pharmaceuticals and 6 mentions for Natera. Natera's average media sentiment score of 0.50 beat Alnylam Pharmaceuticals' score of 0.19 indicating that Natera is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Natera	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alnylam Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alnylam Pharmaceuticals has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Natera	$2.31B	25.65	-$208.16M	-$1.36	N/A
Alnylam Pharmaceuticals	$3.71B	7.92	$313.75M	$5.38	40.84

Natera has a beta of 1.5, indicating that its stock price is 50% more volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.28, indicating that its stock price is 72% less volatile than the broader market.

99.9% of Natera shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 5.1% of Natera shares are owned by company insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Alnylam Pharmaceuticals beats Natera on 10 of the 15 factors compared between the two stocks.

How does Alnylam Pharmaceuticals compare to argenex?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and argenex (NASDAQ:ARGX) are both large-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, profitability, risk, dividends, earnings and analyst recommendations.

In the previous week, Alnylam Pharmaceuticals had 5 more articles in the media than argenex. MarketBeat recorded 8 mentions for Alnylam Pharmaceuticals and 3 mentions for argenex. Alnylam Pharmaceuticals' average media sentiment score of 0.19 beat argenex's score of 0.05 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
argenex	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alnylam Pharmaceuticals presently has a consensus target price of $366.90, indicating a potential upside of 66.99%. argenex has a consensus target price of $1,158.61, indicating a potential upside of 26.04%. Given Alnylam Pharmaceuticals' higher probable upside, analysts clearly believe Alnylam Pharmaceuticals is more favorable than argenex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.83
argenex	0 Sell rating(s)	5 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.88

argenex has a net margin of 32.19% compared to Alnylam Pharmaceuticals' net margin of 15.26%. Alnylam Pharmaceuticals' return on equity of 84.93% beat argenex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%
argenex	32.19%	43.59%	36.66%

Alnylam Pharmaceuticals has a beta of 0.28, suggesting that its share price is 72% less volatile than the broader market. Comparatively, argenex has a beta of 0.45, suggesting that its share price is 55% less volatile than the broader market.

93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 60.3% of argenex shares are owned by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are owned by insiders. Comparatively, 2.4% of argenex shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

argenex has higher revenue and earnings than Alnylam Pharmaceuticals. argenex is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$3.71B	7.92	$313.75M	$5.38	40.84
argenex	$5.23B	11.00	$1.29B	$26.04	35.30

Summary

argenex beats Alnylam Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Alnylam Pharmaceuticals compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, media sentiment, dividends, analyst recommendations and institutional ownership.

Revolution Medicines presently has a consensus price target of $234.33, indicating a potential upside of 13.40%. Alnylam Pharmaceuticals has a consensus price target of $366.90, indicating a potential upside of 66.99%. Given Alnylam Pharmaceuticals' higher probable upside, analysts plainly believe Alnylam Pharmaceuticals is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	20 Buy rating(s)	2 Strong Buy rating(s)	2.96
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.83

Alnylam Pharmaceuticals has a net margin of 15.26% compared to Revolution Medicines' net margin of 0.00%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-88.20%	-57.85%
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%

Alnylam Pharmaceuticals has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$11.58M	3,824.80	-$1.13B	-$8.82	N/A
Alnylam Pharmaceuticals	$3.71B	7.92	$313.75M	$5.38	40.84

In the previous week, Revolution Medicines had 6 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 14 mentions for Revolution Medicines and 8 mentions for Alnylam Pharmaceuticals. Revolution Medicines' average media sentiment score of 0.57 beat Alnylam Pharmaceuticals' score of 0.19 indicating that Revolution Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alnylam Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Revolution Medicines has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.28, indicating that its stock price is 72% less volatile than the broader market.

94.3% of Revolution Medicines shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 7.6% of Revolution Medicines shares are owned by insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Revolution Medicines and Alnylam Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

Get Alnylam Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALNY vs. The Competition

Export

Metric	Alnylam Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$29.40B	$3.86B	$7.16B	$13.28B
Dividend Yield	N/A	3.65%	2.54%	17.32%
P/E Ratio	40.84	7.72	215.53	21.44
Price / Sales	7.92	1,295.82	609.31	92.00
Price / Cash	78.58	123.39	78.87	52.62
Price / Book	36.80	16.63	10.93	6.31
Net Income	$313.75M	-$22.71M	$3.51B	$362.16M
7 Day Performance	-14.16%	-2.99%	-2.00%	-1.66%
1 Month Performance	-16.93%	-10.60%	-6.15%	-4.50%
1 Year Performance	-51.85%	19.44%	7.44%	2.06%

Alnylam Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALNY Alnylam Pharmaceuticals	3.6143 of 5 stars	$219.72 -5.0%	$366.90 +67.0%	-52.3%	$29.40B	$3.71B	40.84	2,770	Analyst Forecast
REGN Regeneron Pharmaceuticals	4.2665 of 5 stars	$736.61 +0.2%	$809.50 +9.9%	+22.5%	$75.86B	$14.34B	18.21	15,410	Trending News Analyst Forecast
MRNA Moderna	1.9454 of 5 stars	$188.65 -0.2%	$77.83 -58.7%	+569.8%	$75.38B	$1.94B	N/A	4,700	Trending News Analyst Downgrade
NTRA Natera	2.0465 of 5 stars	$406.18 -0.6%	$341.55 -15.9%	+156.1%	$58.15B	$2.31B	N/A	6,140	Analyst Forecast Insider Trade
ARGX argenex	4.5204 of 5 stars	$918.17 -1.9%	$1,158.61 +26.2%	+16.1%	$57.42B	$4.25B	35.25	1,863

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALNY) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alnylam Pharmaceuticals (ALNY) Competitors

ALNY vs. REGN, MRNA, NTRA, ARGX, and RVMD

How does Alnylam Pharmaceuticals compare to Regeneron Pharmaceuticals?

Summary

How does Alnylam Pharmaceuticals compare to Moderna?

Summary

How does Alnylam Pharmaceuticals compare to Natera?

Summary

How does Alnylam Pharmaceuticals compare to argenex?

Summary

How does Alnylam Pharmaceuticals compare to Revolution Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALNY vs. The Competition

Alnylam Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alnylam Pharmaceuticals (ALNY) Competitors

ALNY vs. REGN, MRNA, NTRA, ARGX, and RVMD

How does Alnylam Pharmaceuticals compare to Regeneron Pharmaceuticals?

Which has preferable earnings & valuation, REGN or ALNY?

Is REGN or ALNY more profitable?

Which has more volatility & risk, REGN or ALNY?

Do analysts recommend REGN or ALNY?

Do institutionals and insiders believe in REGN or ALNY?

Does the media refer more to REGN or ALNY?

Summary

How does Alnylam Pharmaceuticals compare to Moderna?

Which has more risk & volatility, ALNY or MRNA?

Does the media prefer ALNY or MRNA?

Do analysts prefer ALNY or MRNA?

Do insiders & institutionals hold more shares of ALNY or MRNA?

Is ALNY or MRNA more profitable?

Which has preferable earnings and valuation, ALNY or MRNA?

Summary

How does Alnylam Pharmaceuticals compare to Natera?

Do analysts recommend NTRA or ALNY?

Is NTRA or ALNY more profitable?

Does the media prefer NTRA or ALNY?

Which has stronger valuation & earnings, NTRA or ALNY?

Which has more risk and volatility, NTRA or ALNY?

Do insiders & institutionals have more ownership in NTRA or ALNY?

Summary

How does Alnylam Pharmaceuticals compare to argenex?

Does the media refer more to ALNY or ARGX?

Do analysts recommend ALNY or ARGX?

Is ALNY or ARGX more profitable?

Which has more volatility and risk, ALNY or ARGX?

Do insiders and institutionals believe in ALNY or ARGX?

Which has better earnings and valuation, ALNY or ARGX?

Summary

How does Alnylam Pharmaceuticals compare to Revolution Medicines?

Do analysts prefer RVMD or ALNY?

Is RVMD or ALNY more profitable?

Which has higher valuation & earnings, RVMD or ALNY?

Does the media prefer RVMD or ALNY?

Which has more risk and volatility, RVMD or ALNY?

Do institutionals and insiders have more ownership in RVMD or ALNY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALNY vs. The Competition

Alnylam Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools